Single-cell and #SpatialTranscriptomics of primary testicular #DLBCL reveal an exhausted CD8⁺ T cell–dominated microenvironment and spatial immune architecture, with E2F and CREB inhibition suppressing #lymphoma proliferation and #tumor growth.
#OpenAccess: doi.org/10.1016/j.ge...
ADC Therapeutics Announces 2025 Financial Outcomes and Future Directions in ADCT Operations #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #DLBCL
We’ve launched a new diffuse large B-cell lymphoma #DLBCL Working Group!🙌
The kickoff brought together members and prospective members to discuss the focus and proposal for the group. Excited to expand into this space and get started.
Michael Acceptor Pyrrolidone Derivatives and Their Activity against Diffuse Large B-cell Lymphoma
In this study, the researchers spotlight the #Antitumor potential of variant 7 among synthesized pyrrolidone compounds in #DLBCL cell lines, which induces #DNAdamage, #Inflammatory responses, #CellCycle arrest, & #Apoptosis. #medsky
To read: doi.org/10.1007/s115...
血液がん治療の最新情報を学ぶセミナーが開催されます！ #東京都 #文京区 #キャンサーネットジャパン #血液がん #DLBCL
5月12日にオンラインで「びまん性大細胞型B細胞リンパ腫」に関するセミナーを開催。参加無料、冊子プレゼントにも注目！
On #RareDiseaseDay, we highlight how #SYNTHIA supports research in rare cancers. Using #syntheticdata, our work in #multiplemyeloma and #DLBCL strengthens clinical trials and improves outcome prediction.
#PersonalisedMedicine #HealthInnovation #EUResearch #IHITransformingHealth #HorizonEU
Clinical Snapshot: #DLBCL QoL Reporting 📊
• Data: Clinicians underreport symptoms vs patients (Kappa 0.16–0.44).
• Impact: Leads to inaccurate risk assessments.
From @bloodjournals.hematology.org. Read: https://bit.ly/4u2XCuL
#HemeOnc #lymsm
Real‑world Austrian data show limits of standard chemo for many DLBCL patients and highlight the need for newer therapies. www.hematologyadvisor.com/news/real-world-austrian...
#DLBCL #CancerCare #Oncology #ChemoLimitations #NewTreatments
Standard #Chemotherapy-based approaches for diffuse large B-cell lymphoma (#DLBCL) produced acceptable outcomes in lower-risk patients but consistently poor results in high-risk disease and after frontline failure.
Read more: https://bit.ly/4rM6Slv
#RareDisease #DiffuseLargeBCellLymphoma
Blue graphic with the text "3 Facts About Diffuse large B-cell lymphoma (DLBCL)" and a "Swipe" instruction. The Rare Disease Advisor logo is at the bottom. Geometric patterns decorate the background.
Blue graphic with the number 1 at the top. Text reads: "DLBCL is the most common cancer of the lymphatic system, comprising approximately 30% to 40% of cases of non-Hodgkin lymphoma (NHL).
The image has a blue background with a large number "2" at the top. Below, it reads: "The estimated incidence rate for DLBCL is 4.68 cases per 100,000 per year." White diagonal lines are in the corners.
A blue background with number 3 at the top. Text reads: "Over 700 genetic variations and 150 genetic drivers contribute to the development of DLBCL, often involving chromosomal translocations of BCL2, BCL6, and MYC genes.
💡 Discover 3 Facts About Diffuse Large B-Cell Lymphoma (#DLBCL)
Learn more at our Resource Page: https://bit.ly/46v3Mdk
#WorldCancerDay #RareCancer #RareDisease
The results of this recent Blood Cancer Discovery study provide a strong rationale for continued clinical investigation of golcadomide for patients with #DLBCL.
👉 Read more: Golcadomide for Diffuse Large B-cell #Lymphoma buff.ly/brkj0WM #lymsm #bcellmalignancies
#Epcoritamab improved progression-free survival (#PFS) compared with investigator’s choice chemoimmunotherapy in adults with relapsed or refractory (R/R) #DLBCL, although overall survival was not significantly different.
Read more: https://bit.ly/4qclfxv
#MedSky #RareDisease
CD20-targeting bispecific antibodies including epcoritamab and glofitamab may be effective against R/R #DLBCL in the real-world setting, though survival rates were lower than those noted in pivotal clinical trials. Published in @bloodjournals.hematology.org.
https://bit.ly/3ZFUiYc
#lymsm
Patients generally reported a higher incidence of common symptoms compared with clinician reports. Pola-R-CHP and R-CHOP similarly improved HRQoL and lymphoma symptoms in previously untreated DLBCL. Read in Blood: buff.ly/ugYu3lY #DLBCL #Blood
ZR2 produced high remission rates and durable survival in adults aged 75 years and older with newly diagnosed #DLBCL. Published in @bloodjournals.hematology.org.
https://bit.ly/4jEkCLv
#lymphoma #lymsm
AbbVie Shares Promising Phase 3 Data for Epcoritamab in DLBCL Patients #USA #Epcoritamab #AbbVie #North_Chicago #DLBCL
🔗 Read more: bit.ly/ONCOnews06J-01
#ONCOnews #OncoAlert #OncEd #DLBCL #Lymphoma #Oncology #ClinicalTrials
Integrating single-cell RNA-seq with spatial transcriptomics reveals immune niches and tumor architecture in testicular DLBCL.
#SpatialTranscriptomics #scRNAseq #DLBCL #TME
www.sciencedirect.com/science/arti...
6️⃣To support broader adoption of #ctDNA in #DLBCL, we have made our end-to-end pipeline AULE (Automated Ultrasensitive Lymphoma Evaluation) pipeline fully open-source on GitHub: github.com/Hodson-Bioin... #DIRECT
4️⃣One of the most important takeaways from #DIRECT is that the Limit of Detection (LoD) is not an "one-size-fits-all" figure. It is patient rather than assay specific. We found that this limit varied by more than two orders of magnitude across different patients. #DLBCL #ctDNA
3️⃣We identified a key nuance: persistent PV-MRD does not always predict relapse, especially in transformed follicular lymphoma (tFL). In our cohort, 75% (3/4) of tFL cases remained #MRD-positive without relapse, likely due to a persisting indolent subclone. #DLBCL #ctDNA #DIRECT
2️⃣PV-MRD status significantly outperformed conventional PET-CT scans at EoT (HR 16.9 vs. 6.9). Perhaps most importantly, we found that for patients with a positive PET scan but negative PV-#MRD, the 2-year TTP remained high at ~91% #DLBCL #ctDNA #DIRECT
1️⃣Clearing PV-MRD at the end of 1L therapy is a powerful predictor of success: patients with undetectable #MRD had a 95% 2-year time to tumor progression (TTP), compared to just 42% for those with detectable levels. #DLBCL #ctDNA #DIRECT
Antengene Secures Approval for XPOVIO® to Treat DLBCL in Malaysia #Malaysia #Kuala_Lumpur #DLBCL #Antengene #XPOVIO®
MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
Adding ibrutinib to SOC R-CHOP resulted in a 77.7% PFS rate at 2 years among younger adults with intermediate or high risk ABC #DLBCL. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.
https://bit.ly/3XTrlay
#lymsm
JAMA Network Open article: "Prebiopsy Steroids and Diagnostic Yield in Patients With Diffuse Large B-Cell Lymphoma" by Sathwik Madireddy, Sovijja Pou, Kaavya Mandi et al. Published Dec 11, 2025.
This study found no association between pre-biopsy corticosteroid exposure and diagnostic yield in patients with newly diagnosed diffuse large B-cell lymphoma, suggesting steroids can be used when appropriate without compromising diagnosis. #DLBCL ja.ma/48W4q3E
A “smart” strategy of targeted therapy first allowed more than half of patients with #DLBCL to achieve CR without chemotherapy. Presented at #ASH25 by @lymphomadoc.bsky.social from @mdanderson.bsky.social.
Read more here: ➡️ https://bit.ly/4aC6KyW
#lymsm
